The Role of Immunotherapy as a Treatment Option in Advanced CSCC
A closer look at data for the PD-1 inhibitor LIBTAYO® (cemiplimab-rwlc) from the largest prospective clinical dataset in advanced CSCC. LIBTAYO is indicated for the treatment of patients with mCSCC or laCSCC who are not...
Read More